The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab.
 
Yu-Wei Chen
No Relationships to Disclose
 
Matthew D Tucker
No Relationships to Disclose
 
Hesham Yasin
No Relationships to Disclose
 
Kristin Kathleen Ancell
No Relationships to Disclose
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Taris BioMedical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Jounce Therapeutics; Taris BioMedical
 
Scott Mattox Haake
Expert Testimony - Nature's Bounty
 
Elizabeth Kaiser
No Relationships to Disclose
 
Renee McAlister
Consulting or Advisory Role - Immunocore; Myovant Sciences; Sanofi/Regeneron
 
Wendy Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Publishing (I); Sitryx (I)
Honoraria - Merck (I); pfizer (I)
Consulting or Advisory Role - Caribou Biosciences (I); Sitryx (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (I); Calithera Biosciences (Inst); Incyte (I); Kadmon (I); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Tempus (I)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
Travel, Accommodations, Expenses - Caribou Publishing (I); Chinese Society for Immunology (I); Merck (I); Pfizer (I)
 
Kerry Schaffer
Consulting or Advisory Role - Janssen Biotech
Research Funding - Tempus (Inst)
 
Deborah Wallace
No Relationships to Disclose
 
Katy Beckermann
Consulting or Advisory Role - Aravive; Bristol-Myers Squibb; Exelixis; Seagen
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer